Clinical Trials Directory

Trials / Completed

CompletedNCT02463448

Autologous Muscle Derived Cells for Underactive Bladder

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
23 (actual)
Sponsor
Jason Gilleran · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a prospective, open-label, Phase 1, single center study evaluating the safety and efficacy of Autologous Muscle Derived Cells as a treatment for chronic Underactive Bladder.

Detailed description

Subject that meet inclusion and exclusion criteria will be consented and enrolled in this study. Initial screening includes blood and urine testing, questionnaires, physical examination, specialized bladder function testing and review of medical history. At the next visit a small sample of each subject's own thigh muscle is obtained by needle biopsy. This cell biopsy is sent to a specialized lab for growth and processing. Approximately ten weeks later the frozen cells will be sent back to the treatment site for thawing, diluting and injection under lighted instrumentation into the subject's bladder wall. The subject will be followed for 6 months and at that time may be eligible for a second injection of cells. The study doctor will determine if the second injection may be beneficial to the subject. All subjects will be followed for up to 12 months. The follow-up assessments at 12 months will include questionnaires, urine and blood testing, specialized bladder function testing and visualizing the inside of the bladder with a lighted instrument.

Conditions

Interventions

TypeNameDescription
BIOLOGICALAutologous Muscle Derived CellsA small sample of the subject's own thigh muscle is obtained by needle biopsy. The biopsy sample is sent to Cook Myosite, Inc. for growth and processing. When the sample cell dosage is achieved the cells are frozen and sent back to the treatment site. The cells are thawed, diluted and injected under lighted instrumentation and visualization into about 30 sites in the bladder wall.

Timeline

Start date
2016-11-16
Primary completion
2019-12-01
Completion
2020-11-01
First posted
2015-06-04
Last updated
2022-01-19
Results posted
2022-01-19

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02463448. Inclusion in this directory is not an endorsement.